Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nanjing Medical University has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners in 2 distinct art units. This separation means that each of the university's current pending matters is being evaluated independently by different technical experts in 2 different divisions of the USPTO. The 2 pending office actions do not share any common personnel or art unit oversight.
The busiest examiner, ZHU, JIANJIAN, is responsible for 1 pending office action. This distribution indicates that each of the 2 pending office actions is proceeding along a separate prosecution path. Practitioners must be prepared to address the specific preferences of 2 distinct examiners and the unique standards of 2 distinct art units. With no overlap between the 2 pending office actions, the university's prosecution strategy must be highly individualized for each case to account for the different perspectives of the 2 examiners involved in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549322 | A METHOD FOR CONSTRUCTING A MOUSE MODEL WITH SHORT TELOMERE | ZHU, JIANJIAN | — |
| 18293068 | SERUM CIRCRNA MARKER FOR RECOGNIZING CRANIOSYNOSTOSIS AND APPLICATION THEREOF | KAPUSHOC, STEPHEN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549322 | A METHOD FOR CONSTRUCTING A MOUSE MODEL WITH SHORT TELOMERE | ZHU, JIANJIAN | — |
| 18293068 | SERUM CIRCRNA MARKER FOR RECOGNIZING CRANIOSYNOSTOSIS AND APPLICATION THEREOF | KAPUSHOC, STEPHEN THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18549322 | A METHOD FOR CONSTRUCTING A MOUSE MODEL WITH SHORT TELOMERE | ZHU, JIANJIAN | 1631 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18293068 | SERUM CIRCRNA MARKER FOR RECOGNIZING CRANIOSYNOSTOSIS AND APPLICATION THEREOF | KAPUSHOC, STEPHEN THOMAS | 1683 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Medical University has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jianjian Zhu has the most, with 1 of Nanjing Medical University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
